Graves病初始治疗与心血管疾病发病率和死亡率:一项关联记录队列研究
BACKGROUND: Graves' disease is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncertain.…
核心结论
- 无论采用何种治疗方式,Graves病患者早期有效控制甲亢与改善生存相关。
- 应优先实现甲亢快速持续控制,对单用抗甲状腺药物不太可能缓解者应早期提供确定性放射性碘治疗。
研究设计与样本
- 回顾性队列研究,从英国南威尔士TSH受体抗体检测登记中识别1998年至2013年诊断的甲亢患者,数据导入SAIL数据库。
- 按诊断1年内治疗分为抗甲状腺药物组、放射性碘治疗且甲亢缓解组(放射性碘A组)、放射性碘治疗且甲亢未缓解组(放射性碘B组)。
- 采用landmark Kaplan-Meier和Cox回归模型分析,landmark设定为诊断后1年。
主要发现
- landmark分析中,抗甲状腺药物组3587例,放射性碘A组250例,放射性碘B组182例。
- 样条回归显示诊断后1年FT4浓度与全因死亡率呈正非线性关系。
临床怎么用
- Graves病管理应优先实现甲亢快速且持续的控制。
- 对单用抗甲状腺药物不太可能达到缓解的患者,应考虑早期确定性放射性碘治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Graves' disease is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncertain. We evaluated cardiovascular morbidity and mortality according to the method and effectiveness of primary therapy in Graves' disease. METHODS: In this retrospective cohort study, we identified patients with hyperthyroidism, diagnosed between Jan 1, 1998, and Dec 31, 2013, from a thyroid-stimulating hormone (TSH)-receptor antibody (TRAb) test register in south Wales, UK, and imported their clinical data into the All-Wales Secure Anonymised Information Linkage (SAIL) Databank (Swansea University, Swansea, UK). Patients with Graves' disease, defined by positive TRAb tests, were selected for the study, and their clinical data were linked with outcomes in SAIL. We had no exclusion criteria. Patients were matched by age and sex to a control population (1:4) in the SAIL database. Patients were grouped by treatment within 1 year of diagnosis into the antithyroid drug group, radioiodine with resolved hyperthyroidism group (radioiodine group A), or radioiodine with unresolved hyperthyroidism group (radioiodine group B). We used landmark Kaplan-Meier and Cox regression models to analyse the association of treatment with the primary outcome of all-cause mortality and the secondary outcome of major adverse cardiovascular events (myocardial infarction, heart failure, ischaemic stroke, or death) with the landmark set at 1 year after diagnosis. We analysed the association between outcomes and concentration of TSH using Cox regression and outcomes and free thyroxine (FT4) concentration using restricted cubic-spline regression models. FINDINGS: We extracted patient-level data on 4189 patients (3414 [81·5%] females and 775 [18·5%] males) with Graves' disease and 16 756 controls (13 656 [81·5%] females and 3100 [18·5%] males). In landmark analyses, 3587 patients were in the antithyroid drug group, 250 were in radioiodine group A, 182 were in radioiodine group B. Patients had increased all-cause mortality compared with controls (hazard ratio [HR] 1·22, 95% CI 1·05-1·42). Compared with patients in the antithyroid drug group, mortality was lower among those in radioiodine group A (HR 0·50, 95% CI 0·29-0·85), but not for those in radioiodine group B (HR 1·51, 95% CI 0·96-2·37). Persistently low TSH concentrations at 1 year after diagnosis were associated with increased mortality independent of treatment method (HR 1·55, 95% CI 1·08-2·24). Spline regressions showed a positive non-linear relationship between FT4 concentrations at 1 year and all-cause mortality. INTERPRETATION: Regardless of the method of treatment, early and effective control of hyperthyroidism among patients with Graves' disease is associated with improved survival compared with less effective control. Rapid and sustained control of hyperthyroidism should be prioritised in the management of Graves' disease and early definitive treatment with radioiodine should be offered to patients who are unlikely to achieve remission with antithyroid drugs alone. FUNDING: National Institute for Social Care and Health Research, Wales.
引用
- Okosieme OE, Taylor PN, Evans C, et al. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019. PMID: 30827829. doi:10.1016/S2213-8587(19)30059-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。